Correction: Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma (PLoS ONE (2013) 8:11 (e82478) DOI: 10.1371/journal.pone.0082478);Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Lee, Yung Kuo ^a   Lin, Tsung Hsien ^b   Chang, Chuan Fa ^a   Lo, Yu Li ^b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL UNIVERSITY OF TAINAN   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BETA CATENIN; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; EPIRUBICIN; GALECTIN 3; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL LEVEL; CELL STRAIN CACO 2; CHROMATIN CONDENSATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; METABOLIC REGULATION; MITOCHONDRION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BCL-2-ASSOCIATED X PROTEIN; BETA CATENIN; CACO-2 CELLS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN D1; EPIRUBICIN; GALECTIN 3; GENE SILENCING; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MITOCHONDRIA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84896718145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107784     Document Type: Erratum

References (43)

1. Akhter M, Inoue M, Kurahashi N, Iwasaki M, Sasazuki S et al. (2008) Dietary soy and isoflavone intake and risk of colorectal cancer in the Japan public health center-based prospective study. Cancer Epidemiol Biomarkers Prev 17: 2128-2135. doi:10.1158/1055-9965.EPI-08-0182. PubMed: 18708407.
2. Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1: 55-67. doi:10.1038/35094067. PubMed: 11900252. (Pubitemid 33741881)
3. Lo YL, Wang W, Ho CT (2012) 7,3',4'-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicology 302: 221-232. doi:10.1016/j.tox.2012.08.003. PubMed: 22914566.
4. Xia Z, Zhang L, Chen Q, Royal C, Yu Z et al. (2009) Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene. Mol Med Rep 2: 579-584. PubMed: 21475869.
5. Alemán C, Annereau JP, Liang XJ, Cardarelli CO, Taylor B et al. (2003) P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 63: 3084-3091. PubMed: 12810633. (Pubitemid 36735857)
6. Dumic J, Dabelic S, Flögel M (2006) Galectin-3: an open-ended story. Biochim Biophys Acta 1760: 616-635. doi:10.1016/j.bbagen.2005.12.020. PubMed: 16478649. (Pubitemid 44382499)
7. Endo K, Kohnoe S, Tsujita E, Watanabe A, Nakashima H et al. (2005) Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 25: 3117-3121. PubMed: 16080575.
8. Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M et al. (1999) Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15: 143-148. PubMed: 10375607.
9. Shi Y, He B, Kuchenbecker KM, You L, Xu Z et al. (2007) Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer 121: 1175-1181. doi:10.1002/ijc.22848. PubMed: 17534895. (Pubitemid 47293782)
10. Zaia Povegliano L, Oshima CT, de Oliveira Lima F, Andrade Scherholz PL, Manoukian Forones N (2011) Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival. J Gastrointest Cancer 42: 217-221. doi:10.1007/s12029-010-9189-1. PubMed: 20635166.
11. Castronovo V, Campo E, van den Brûle FA, Claysmith AP, Cioce V et al. (1992) Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 84: 1161-1169. doi:10.1093/jnci/84.15.1161. PubMed: 1386115.
12. Lotz MM, Andrews CW Jr., Korzelius CA, Lee EC, Steele GD Jr. et al. (1993) Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci U S A 90: 3466-3470. doi:10.1073/pnas.90.8. 3466. PubMed: 7682704. (Pubitemid 23111387)
13. Iacovazzi PA, Notarnicola M, Caruso MG, Guerra V, Frisullo S et al. (2010) Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol Immunotoxicol 32: 160-164. doi:10.3109/ 08923970902936880. PubMed: 19686089.
14. Greco C, Vona R, Cosimelli M, Matarrese P, Straface E et al. (2004) Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions. Glycobiology 14: 783-792. doi:10.1093/glycob/cwh092. PubMed: 15140826. (Pubitemid 39206881)
15. Saegusa J, Hsu DK, Liu W, Kuwabara I, Kuwabara Y et al. (2008) Galectin-3 protects keratinocytes from UVB-induced apoptosis by enhancing AKT activation and suppressing ERK activation. J Invest Dermatol 128: 2403-2411. doi:10.1038/jid.2008.119. PubMed: 18463681.
16. Cheng YL, Huang WC, Chen CL, Tsai CC, Wang CY et al. (2011) Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun 412: 334-340. doi:10.1016/j.bbrc.2011.07.099. PubMed: 21821001.
17. Lin CI, Whang EE, Abramson MA, Donner DB, Bertagnolli MM et al. (2009) Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 379: 626-631. doi:10.1016/j.bbrc.2008.12.153. PubMed: 19124005.
18. Nakahara S, Raz A (2007) Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev 26: 605-610. doi:10.1007/s10555-007-9095-6. PubMed: 17726578. (Pubitemid 350115124)
19. Song S, Mazurek N, Liu C, Sun Y, Ding QQ et al. (2009) Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 69: 1343-1349. doi:10.1158/0008-5472.CAN-08-4153. PubMed: 19190323.
20. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A et al. (2004) Galectin-3, a novel binding partner of beta-catenin. Cancer Res 64: 6363-6367. doi:10.1158/0008-5472.CAN-04-1816. PubMed: 15374939. (Pubitemid 39297885)
21. Gutmann H, Fricker G, Török M, Michael S, Beglinger C et al. (1999) Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm Res 16: 402-407. doi:10.1023/A:1018825819249. PubMed: 10213371. (Pubitemid 29162098)
22. Lo YL, Ho CT, Tsai FL (2008) Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur J Pharm Sci 35: 52-67. doi:10.1016/j.ejps.2008.06.003. PubMed: 18606222.
23. Lo YL (2012) A potential daidzein derivative enhances cytotoxicity of epirubicin on human colon adenocarcinoma caco-2 cells. Int J Mol Sci 14: 158-176. doi:10.3390/ijms14010158. PubMed: 23344026.
24. Marbeuf-Gueye C, Salerno M, Quidu P, Garnier-Suillerot A (2000) Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. Eur J Pharmacol 391: 207-216. doi:10.1016/S0014-2999(00)00047-9. PubMed: 10729360. (Pubitemid 30154086)
25. Wu CP, Calcagno AM, Ambudkar SV (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1: 93-105. doi:10.2174/1874467210801020093. PubMed: 19079736.
26. Wang X, Wang C, Qin YW, Yan SK, Gao YR (2007) Simultaneous suppression of multidrug resistance and antiapoptotic cellular defense induces apoptosis in chemoresistant human acute myeloid leukemia cells. Leuk Res 31: 989-994. doi:10.1016/j.leukres.2006.09.001. PubMed: 17067671. (Pubitemid 46856717)
27. Pallis M, Russell N (2000) P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 95: 2897-2904. PubMed: 10779437. (Pubitemid 30235901)
28. Xu Y, Xia F, Ma L, Shan J, Shen J et al. (2011) MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 310: 160-169. PubMed: 21802841.
29. Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K et al. (2000) Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 60: 4761-4766. PubMed: 10987283.
30. Lee WK, Chakraborty PK, Thévenod F (2013) Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1. Int J Cancer, 133: 556-67. PubMed: 23354914.
31. Seo SB, Hur JG, Kim MJ, Lee JW, Kim HB et al. (2010) TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol Cancer 9: 199. doi:10.1186/1476-4598-9-199. PubMed: 20663232.
32. Nakamura Y, Sato H, Motokura T (2006) Development of multidrug resistance due to multiple factors including P-glycoprotein overexpression under K-selection after MYC and HRAS oncogene activation. Int J Cancer 118: 2448-2454. doi:10.1002/ijc.21691. PubMed: 16353156.
33. Chen Y, Bathula SR, Li J, Huang L (2010) Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 285: 22639-22650. doi:10.1074/jbc.M110.125906. PubMed: 20460382.
34. Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y et al. (2010) Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 9: 145. doi:10.1186/1476-4598-9-145. PubMed: 20540746.
35. Huang WC, Tsai CC, Chen CL, Chen TY, Chen YP et al. (2011) Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis. FASEB J 25: 3661-3673. doi:10.1096/fj.10-180190. PubMed: 21705667.
36. Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK et al. (2008) Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem 106: 1855-1865. PubMed: 18624906.
37. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV et al. (1999) Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59: 3505-3511. PubMed: 10416617. (Pubitemid 29334515)
38. Fukumori T, Kanayama HO, Raz A (2007) The role of galectin-3 in cancer drug resistance. Drug Resist Updat 10: 101-108. doi:10.1016/j.drup.2007.04.001. PubMed: 17544840. (Pubitemid 47031053)
39. Yamamoto-Sugitani M, Kuroda J, Ashihara E, Nagoshi H, Kobayashi T et al. (2011) Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 108: 17468-17473. doi:10.1073/pnas.1111138108. PubMed: 21987825.
40. Kobayashi T, Shimura T, Yajima T, Kubo N, Araki K et al. (2011) Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of beta-catenin. Int J Cancer 129: 2775-2786. doi:10.1002/ijc.25946. PubMed: 21448903.
41. Takahashi-Yanaga F, Sasaguri T (2008) GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 20: 581-589. doi:10.1016/j.cellsig.2007.10.018. PubMed: 18023328. (Pubitemid 351241128)
42. Cheong TC, Shin JY, Chun KH (2010) Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci 101: 94-102. doi:10.1111/j.1349-7006.2009. 01364.x. PubMed: 19843071.
43. Mao Y, Li Z, Lou C, Zhang Y (2011) Expression of phosphorylated Stat5 predicts expression of cyclin D1 and correlates with poor prognosis of colonic adenocarcinoma. Int J Colorectal Dis 26: 29-35. doi:10.1007/s00384-010-1090-7. PubMed: 21079973.